Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 5 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.

Septal myectomy safe for hypertrophic cardiomyopathy

11 Jul 2020
At least a dozen children have infected incisions, after undergoing heart surgery at the hospital – allegedly from contaminated equipment.

Septal myectomy is a safe procedure, bearing minimal risk of early mortality and adverse events, a recent study has found.

The researchers conducted a prospective analysis on 345 patients (mean age, 55.0±13.4 years; 44.9 percent male) with hypertrophic cardiomyopathy who underwent treatment via surgical myectomy. The primary study endpoint was 30-day mortality, while other outcomes of interest included long-term survival and freedom from sudden cardiac death and recurrent atrial tachyarrhythmia.

One male and five female patients died within 30 days of surgery, yielding a short-term mortality rate of 1.7 percent. Most of these patients were above 60 years of age, save for one, who was aged 58 years. Logistic regression analysis did not find any predictor of 30-day mortality.

Thirteen patients (3.8 percent) developed acute renal failure, while nine (2.6 percent) had bleeding that required revision. There were six (1.7 percent) cases of postoperative pericarditis that needed pericardiocentesis. Twenty-nine patients needed permanent pacemakers implanted after surgery.

Almost all (95.4 percent; n=329) of the participants were still able to attend the last follow-up assessment, at which time most of them (77.2 percent; n=254) were categorized as being of the New York Heart Association class I. At 38 months of follow-up, 97.0±1.0 percent of patients attained freedom from all-cause death.

Seven late-term deaths were reported, and the 5-year overall long-term survival rate after myectomy was 95.7±1.7 percent. This was not significantly different than in age- and sex-matched general-population controls (p=0.109).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 5 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.